Harvard Bioscience Inc [HBIO] stock is trading at $0.59, up 4.24%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HBIO shares have lost -0.35% over the last week, with a monthly amount drifted -28.05%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harvard Bioscience Inc [NASDAQ: HBIO] stock has seen the most recent analyst activity on March 10, 2023, when The Benchmark Company upgraded its rating to a Buy and also boosted its price target to $4 from $3. Previously, The Benchmark Company upgraded its rating to Buy on January 07, 2021. On December 09, 2020, Northland Capital initiated with a Outperform rating and assigned a price target of $6 on the stock. KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and suggested a price target of $6 on November 10, 2020. Janney downgraded its rating to a Neutral but $2 remained the price target by the analyst firm on July 08, 2019. Janney reiterated a Buy rating for this stock on January 24, 2018, and upped its price target to $8. In a note dated January 23, 2018, The Benchmark Company reiterated an Buy rating on this stock and boosted its target price from $6 to $10.
Harvard Bioscience Inc [HBIO] stock has fluctuated between $0.56 and $4.70 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Harvard Bioscience Inc [NASDAQ: HBIO] shares were valued at $0.59 at the most recent close of the market. An investor can expect a potential return of 1086.44% based on the average HBIO price forecast.
Analyzing the HBIO fundamentals
Harvard Bioscience Inc [NASDAQ:HBIO] reported sales of 94.14M for the trailing twelve months, which represents a drop of -12.78%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.19 and Total Capital is -0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5480 points at the first support level, and at 0.5061 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6509, and for the 2nd resistance point, it is at 0.7119.
Ratios To Look Out For
For context, Harvard Bioscience Inc’s Current Ratio is 0.82. Further, the Quick Ratio stands at 0.40, while the Cash Ratio is 0.07. Considering the valuation of this stock, the price to sales ratio is 0.28, the price to book ratio is 0.41.
Transactions by insiders
Recent insider trading involved Green James W, Chief Executive Officer, that happened on Jun 13 ’24 when 10000.0 shares were purchased. Chief Executive Officer, Green James W completed a deal on Jun 06 ’24 to buy 20000.0 shares.
